Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus

JAMA Psychiatry

Volumn 70, Issue 11, 2013, Pages 1199-1205

  Pietrzak, Robert H ^a,b   Gallezot, Jean Dominique ^b   Ding, Yu Shin ^c   Henry, Shannan ^b   Potenza, Marc N ^b   Southwick, Steven M ^a,b   Krystal, John H ^a,b   Carson, Richard E ^b   Neumeister, Alexander ^c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLREBOXETINE C 11; NORADRENALIN TRANSPORTER; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG;

ADULT; ALERTNESS; ANXIETY; AROUSAL; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IN VIVO STUDY; LOCUS CERULEUS; MALE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PTSD SCALE; RATING SCALE; SYMPTOMATOLOGY;

EID: 84888039502     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.399     Document Type: Article

References (44)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision).Washington, DC: American Psychiatric Press; 2000.
2. Pietrzak RH, Tsai J, Harpaz-Rotem I, Whealin JM, Southwick SM. Support for a novel five-factor model of posttraumatic stress symptoms in three independent samples of Iraq/Afghanistan veterans: a confirmatory factor analytic study. J Psychiatr Res. 2012;46(3):317-322.
3. Armour C, Elhai JD, Richardson D, Ractliffe K, Wang L, Elklit A. Assessing a five factor model of PTSD: is dysphoric arousal a unique PTSD construct showing differential relationships with anxiety and depression? J Anxiety Disord. 2012;26(2):368-376.
4. Elhai JD, Biehn TL, Armour C, Klopper JJ, Frueh BC, Palmieri PA. Evidence for a unique PTSD construct represented by PTSD's D1-D3 symptoms. J Anxiety Disord. 2011;25(3):340-345.
5. Armour C, Carragher N, Elhai JD. Assessing the fit of the dysphoric arousal model across two nationally representative epidemiological surveys: the Australian NSMHWB and the United States NESARC. J Anxiety Disord. 2013;27(1):109-115.
6. Pietrzak RH, Henry S, Southwick SM, Krystal JH, Neumeister A. Linking in vivo brain serotonin type 1B receptor density to phenotypic heterogeneity of posttraumatic stress symptomatology. Mol Psychiatry. 2013;18(4):399-401.
7. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci. 1993;16:73-93.
8. Ordway GA, Stockmeier CA, Cason GW, Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci. 1997;17(5):1710-1719.
9. Schwartz JW, Novarino G, Piston DW, DeFelice LJ. Substrate binding stoichiometry and kinetics of the norepinephrine transporter. J Biol Chem. 2005;280(19):19177-19184.
10. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003;4(1):13-25.
11. Zafar HM, Paré WP, Tejani-Butt SM. Effect of acute or repeated stress on behavior and brain norepinephrine system inWistar-Kyoto (WKY) rats. Brain Res Bull. 1997;44(3):289-295.
12. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22(2):389-395.
13. Liprando LA,Miner LH, Blakely RD, Lewis DA, Sesack SR. Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Synapse. 2004;52(4):233-244.
14. Miner LH, Jedema HP, Moore FW, Blakely RD, Grace AA, Sesack SR. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. J Neurosci. 2006;26(5):1571-1578.
15. Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57(11):1377-1384.
16. Logan J, Ding YS, Lin KS, Pareto D, Fowler J, Biegon A. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. Nucl Med Biol. 2005;32(5):531-542.
17. Logan J,Wang GJ, Telang F, et al. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nucl Med Biol. 2007;34(6):667-679.
18. Ding YS, Lin KS, Garza V, et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse. 2003;50(4):345-352.
19. Ding YS, Lin KS, Logan J, Benveniste H, Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([ 11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [ 11C]oxaprotiline and [11C]lortalamine. J Neurochem. 2005;94(2):337-351.
20. National Center for Biotechnology Information. Molecular Imaging and Contrast Agent Database (MICAD). 2004-2013. www.ncbi.nlm.nih.gov/books/NBK5330/. Accessed August 5, 2013.
21. Ghose S, Fujita M, Morrison P, et al. Specific in vitro binding of (S,S)-[3H]MeNER to norepinephrine transporters. Synapse. 2005;56(2):100-104.
22. Gallezot JD,Weinzimmer D, Nabulsi N, et al. Evaluation of [ 11C]MRB for assessment of occupancy of norepinephrine transporters: studies with atomoxetine in non-human primates. Neuroimage. 2011;56(1):268-279.
23. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses ofmethylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68(9):854-860.
24. Kubany ES, Haynes SN, Leisen MB, et al. Development and preliminary validation of a brief broad-spectrum measure of trauma exposure: the Traumatic Life Events Questionnaire. Psychol Assess. 2000;12(2):210-224.
25. Blake DD,Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75-90.
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
27. Montgomery SA, AsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
28. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
29. First MB, Spitzer RL, Gibbons M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research, New York State Psychiatric Institute; 1995.
30. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol. 2007;52(5):1505-1526.
31. Arango V, Underwood MD, Mann JJ. Fewer pigmented neurons in the locus coeruleus of uncomplicated alcoholics. Brain Res. 1994;650(1):1-8.
32. Ding YS, Singhal T, Planeta-Wilson B, et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[11C]O-methylreboxetine and HRRT. Synapse. 2010;64(1):30-38.
33. Collins DL, Zijdenbos AP, Kollokian V, et al. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging. 1998;17(3):463-468.
34. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273-289.
35. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imagingmethods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23(9):1096-1112.
36. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22(10):1271-1281.
37. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
38. Rusnák M, Kvetnanský R, Jeloková J, Palkovits M. Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats. Brain Res. 2001;899(1-2):20-35.
39. Howells FM, Stein DJ, Russell VA. Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance. Metab Brain Dis. 2012;27(3):267-274.
40. Wilson AA, Johnson DP,Mozley D, et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol. 2003;30(2):85-92.
41. . Matuszewich L, Filon ME, Finn DA, Yamamoto BK. Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. Neuroscience. 2002;110(1):41-48.
42. Lapmanee S, Charoenphandhu N, Krishnamra N, Charoenphandhu J. Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. Behav Brain Res. 2012;231(1):20-28.
43. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012;15(6):825-840.
44. Petrakis IL, Ralevski E, Desai N, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012;37(4):996-1004.